Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)
Juergen Rech, Arnd Kleyer, Mikkel Østergaard, Melanie Hagen, Larissa Valor Mendez, Koray Taşçilar, Gerhard Kroenke, Verena Schönau, David Simon, Stefan Kleinert, Xenofon Baraliakos, Jürgen Braun, Axel Hueber, Martin Fleck, Andrea Rubbert-Roth, Frank Behrens, Martin Feuchtenberger, M Zaenker, Reinhard Voll, Cornelia GlaserMaria Filkova, Eugen Feist, Gerd Burmester, Kirsten Karberg, Johannes Strunk, Juan D. Cañete, Ladislav Šenolt, Esperanza Naredo, Georg Schett
Dive into the research topics of 'Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)'. Together they form a unique fingerprint.